Verastem (VSTM) Cash & Current Investments (2011 - 2026)
Verastem (VSTM) recorded quarterly Cash & Current Investments of $181.7 million in Q1 2026, down 11.37% quarter-over-quarter from $205.0 million in Q4 2025, and up 54.53% on a YoY basis from $117.6 million in Q1 2025.
Verastem (VSTM) Cash & Current Investments (2011 - 2026) Analysis & Trends
Verastem's Cash & Current Investments history runs 16 years deep, the most recent figure standing at $181.7 million for Q1 2026.
- In Q1 2026, Cash & Current Investments rose 54.53% year-over-year to $181.7 million; the TTM figure through Mar 2026 stood at $181.7 million (up 54.53% YoY), while the FY2025 annual figure was $205.0 million, up 130.8% from the prior year.
- Cash & Current Investments was $181.7 million for Q1 2026 at Verastem, down from $205.0 million in the prior quarter.
- In the past five years, Cash & Current Investments ranged from a high of $205.0 million in Q4 2025 to a low of $83.4 million in Q2 2024.
- Historically, Cash & Current Investments has averaged $129.1 million across 5 years, with a median of $113.2 million in 2024.
- The sharpest annual moves came in 2024 and 2025: Cash & Current Investments slumped 54.46% in 2024, then surged 130.8% in 2025.
- A 5-year view of Cash & Current Investments shows it stood at $92.0 million in 2022, then soared by 48.99% to $137.1 million in 2023, then slumped by 35.23% to $88.8 million in 2024, then soared by 130.8% to $205.0 million in 2025, then fell by 11.37% to $181.7 million in 2026.
- The last three Cash & Current Investments figures came in at $181.7 million (Q1 2026), $205.0 million (Q4 2025), and $137.7 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 32.30 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 2.13 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 286.70 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 18.44 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 2.77 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 7.20 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 7.25 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Verastem | 407.42 Mn | 225.74 Mn | 15.90 Mn | 181.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 181.68 Mn |
| Dec 31, 2025 | 204.99 Mn |
| Sep 30, 2025 | 137.71 Mn |
| Jun 30, 2025 | 164.32 Mn |
| Mar 31, 2025 | 117.57 Mn |
| Dec 31, 2024 | 88.82 Mn |
| Sep 30, 2024 | 113.18 Mn |
| Jun 30, 2024 | 83.37 Mn |
| Mar 31, 2024 | 110.13 Mn |
| Dec 31, 2023 | 137.13 Mn |
| Sep 30, 2023 | 165.66 Mn |
| Jun 30, 2023 | 183.09 Mn |
| Mar 31, 2023 | 111.20 Mn |
| Dec 31, 2022 | 92.04 Mn |
| Sep 30, 2022 | 103.98 Mn |
| Jun 30, 2022 | 94.31 Mn |
| Mar 31, 2022 | 106.28 Mn |
| Dec 31, 2021 | 153.80 Mn |
| Sep 30, 2021 | 103.42 Mn |
| Jun 30, 2021 | 108.14 Mn |